O manejo da RM requer o envolvimento de uma equipe cardíaca multidisciplinar; os riscos e benefícios das opções de intervenção devem ser avaliados individualmente para cada paciente. É importante determinar se o paciente tem RM primária ou secundária, pois isso afetará as decisões de tratamento.
RM aguda grave
A RM aguda grave se apresenta como uma emergência médica, e é indicada cirurgia imediata.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
Antes da cirurgia, a redução da pós-carga com diuréticos, nitroprussiato de sódio e/ou contrapulsação com balão intra-aórtico pode ser necessária para estabilizar o paciente.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
RM primária grave crônica: pacientes assintomáticos
Não há tratamento clínico para os pacientes assintomáticos com RM primária grave crônica e função ventricular esquerda preservada que se tenha demonstrado melhorar os desfechos clínicos; no entanto, esses pacientes são monitorados e tratados rigorosamente para comorbidades relevantes, como a hipertensão.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
Os pacientes assintomáticos com RM grave são monitorados por ecocardiografia a cada 6 a 12 meses na tentativa de identificar sinais precoces de disfunção ventricular esquerda, que podem se tornar irreversíveis antes do início de sintomas.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
As indicações cirúrgicas incluem a diminuição da função ventricular direita e a elevação das pressões atriais esquerdas. Para os pacientes assintomáticos, a cirurgia é indicada se a fração de ejeção do ventrículo esquerdo (FEVE) for ≤60% ou o diâmetro sistólico final do ventrículo esquerdo (DSFVE) for ≥40 mm.[1]De Bonis M, Al-Attar N, Antunes M, et al. Surgical and interventional management of mitral valve regurgitation: a position statement from the European Society of Cardiology Working Groups on Cardiovascular Surgery and Valvular Heart Disease. Eur Heart J. 2016 Jan 7;37(2):133-9.
https://academic.oup.com/eurheartj/article/37/2/133/2398345
http://www.ncbi.nlm.nih.gov/pubmed/26152116?tool=bestpractice.com
[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[23]Murphy MO, Rao C, Punjabi PP, et al. In patients undergoing mitral surgery for ischaemic mitral regurgitation is it preferable to repair or replace the mitral valve? Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):218-27.
https://academic.oup.com/icvts/article/12/2/218/742349
http://www.ncbi.nlm.nih.gov/pubmed/21088201?tool=bestpractice.com
[24]Sá MP, Ferraz PE, Escobar RR, et al. Preservation versus non-preservation of mitral valve apparatus during mitral valve replacement: a meta-analysis of 3835 patients. Interact Cardiovasc Thorac Surg. 2012 Dec;15(6):1033-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501301
http://www.ncbi.nlm.nih.gov/pubmed/23027596?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
Em geral, o limite para o tratamento cirúrgico da RM primária grave assintomática diminuiu por causa do sucesso significativo de reparo da valva mitral com baixo risco operatório. Os pacientes com FEVE >60% ou DSFVE <40 mm podem ser considerados para cirurgia no caso de novo episódio de fibrilação atrial ou pressão arterial pulmonar sistólica elevada, ou quando houver dilatação significativa do átrio esquerdo (volume do átrio esquerdo ≥60 mL/m² ou diâmetro ≥55 mm), alta probabilidade de reparo durável e baixo risco cirúrgico.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
As diretrizes dos EUA também recomendam considerar a cirurgia nos pacientes assintomáticos com RM primária grave e função sistólica do VE normal (FEVE >60% e DSFVE <40 mm) se houver alta probabilidade de reparo durável (>95%) e baixo risco cirúrgico (<1%), ou se houver um aumento progressivo do tamanho do VE ou diminuição progressiva da fração de ejeção em ≥3 estudos de imagem seriados.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
As opções cirúrgicas incluem:
Reparo da valva mitral[26]Hu X, Zhao Q. Systematic evaluation of the flexible and rigid annuloplasty ring after mitral valve repair for mitral regurgitation. Eur J Cardiothorac Surg. 2011 Aug;40(2):480-7.
https://academic.oup.com/ejcts/article/40/2/480/444804
http://www.ncbi.nlm.nih.gov/pubmed/21295489?tool=bestpractice.com
Substituição de valva mecânica e anticoagulação ou substituição de valva bioprotética.[27]Keeling D, Baglin T, Tait C, et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011 Aug;154(3):311-24.
https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08753.x
http://www.ncbi.nlm.nih.gov/pubmed/21671894?tool=bestpractice.com
[
]
In people with prosthetic heart valves, what are the effects of combined antiplatelet and vitamin K antagonists (VKA) therapy compared with VKA monotherapy?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.406/fullMostre-me a resposta
Quando a cirurgia for indicada, mas não for possível ou deve ser protelada, as diretrizes dos EUA aconselham que seja considerada uma terapia medicamentosa para disfunção sistólica orientada por diretrizes.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
Os pacientes assintomáticos com RM primária grave e sem indicação para cirurgia podem ser tratados com vigilância ativa.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
RM primária grave crônica: pacientes sintomáticos
As diretrizes recomendam a cirurgia para os pacientes sintomáticos com RM primária crônica grave e risco cirúrgico aceitável.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
Para os pacientes sintomáticos que são inoperáveis ou que apresentam alto risco cirúrgico, a intervenção transcateter da valva mitral (reparo transcateter de ponta a ponta) pode ser considerada se a anatomia da valva mitral for favorável.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
Quando a cirurgia for indicada, mas não for possível ou deve ser protelada, as diretrizes dos EUA recomendam que a terapia medicamentosa para disfunção sistólica pode ser considerada.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
As diretrizes europeias recomendam o tratamento medicamentoso alinhado às diretrizes atuais de insuficiência cardíaca para os pacientes com insuficiência cardíaca evidente.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
Os pacientes refratários à terapia medicamentosa e não elegíveis para cirurgia ou reparo transcateter podem receber um tratamento extendido para insuficiência cardíaca: por exemplo, terapia de ressincronização cardíaca e dispositivos de assistência ventricular.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
RM secundária grave crônica
Todos os pacientes com RM secundária sintomática devem ser tratados com terapia medicamentosa orientada por diretrizes em consulta com um cardiologista especialista no manejo da insuficiência cardíaca, junto com a terapia de ressincronização cardíaca para o tratamento da fibrilação atrial, quando indicado.[28]Barnes C, Sharma H, Gamble J, et al. Management of secondary mitral regurgitation: from drugs to devices. Heart. 2024 Aug 14;110(17):1099-106.
https://heart.bmj.com/content/110/17/1099.long
http://www.ncbi.nlm.nih.gov/pubmed/37607812?tool=bestpractice.com
Se os sintomas persistirem apesar de um tratamento clínico ideal, a intervenção da valva mitral pode ser indicada.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
Para os pacientes com RM secundária grave que estão sendo submetidos à revascularização com cirurgia de revascularização miocárdica (CRM), a cirurgia da valva mitral é recomendada concomitantemente.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
As diretrizes europeias também recomendam considerar a cirurgia quando a revascularização não for indicada e o paciente permanecer sintomático apesar de um tratamento clínico ideal e tiver baixo risco cirúrgico.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
Se o risco cirúrgico não for baixo, a intervenção transcateter da valva mitral pode ser considerada.[11]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
As diretrizes dos EUA recomendam considerar a cirurgia da valva mitral para os pacientes com RM secundária grave que forem submetidos a revascularização com CRM e também nos pacientes gravemente sintomáticos (classe III ou IV da New York Heart Association) com RM secundária grave devido à dilatação do anel atrial e FEVE ≥50% quando os sintomas persistirem apesar da terapia para insuficiência cardíaca e fibrilação atrial.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
Para aqueles com FEVE inferior a 50% que permanecem sintomáticos apesar de uma terapia medicamentosa ideal, a intervenção por reparo transcateter da valva mitral ou cirurgia valvar pode ser considerada.[10]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-227.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
http://www.ncbi.nlm.nih.gov/pubmed/33332150?tool=bestpractice.com
[25]Bonow RO, O'Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 May 5;75(17):2236-70.
https://www.sciencedirect.com/science/article/pii/S0735109720304277
http://www.ncbi.nlm.nih.gov/pubmed/32068084?tool=bestpractice.com
O reparo transcateter da valva mitral borda a borda é preferencial para aqueles com anatomia adequada (FEVE 20% a 50%, DSFVE ≤70 mm, pressão sistólica da artéria pulmonar ≤70 mmHg).